t
Barclays PLC filed a Form 8.3 disclosure on 08 May 2025 regarding ALLIANCE PHARMA PLC, reporting its positions and dealings as of 07 May 2025. As of that date, Barclays PLC held a total interest of 6,359,692 (1.17%) and total short positions of 7,034,788 (1.30%) in Alliance Pharma PLC's 1p ordinary shares. Dealings on 07 May 2025 included purchases of 8,831 shares at 0.6460 GBP, sales of 4,055 shares at prices between 0.6459 and 0.6460 GBP, and various cash-settled derivative transactions.
| Date | 8 May 2025 |
| Time | 14:48:41 |
| Category | Holding(s) in company |
| ID | 9422H |
|
FORM 8.3 |
|||||||
|
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY |
|||||||
|
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR |
|||||||
|
MORE |
|||||||
|
Rule 8.3 of the Takeover Code (the "Code") |
|||||||
|
1. |
KEY INFORMATION |
||||||
|
(a) |
Full name of discloser: |
|
Barclays PLC. |
||||
|
(b) |
Owner or controller of interest and short |
|
|||||
|
|
positions disclosed, if different from 1(a): |
||||||
|
(c) |
Name of offeror/offeree in relation to whose |
ALLIANCE PHARMA PLC |
|||||
|
|
relevant securities this form relates: |
||||||
|
(d) |
If an exempt fund manager connected with an |
|
|||||
|
|
offeror/offeree, state this and specify identity of |
||||||
|
|
offeror/offeree: |
||||||
|
(e) |
Date position held/dealing undertaken: |
07 May 2025 |
|||||
|
(f) |
In addition to the company in 1(c) above, is the discloser making |
NO |
|
|
|||
|
|
disclosures in respect of any other party to the offer? |
|
|
||||
|
2. |
POSITIONS OF THE PERSON MAKING THE DISCLOSURE |
||||||
|
(a) |
Interests and short positions in the relevant securities of the offeror or offeree |
|
|||||
|
|
to which the disclosure relates following the dealing(if any) |
|
|||||
|
Class of relevant security: |
1p ordinary |
||||||
|
|
Interests |
Short Positions |
|||||
|
|
Number |
(%) |
Number |
(%) |
|||
|
(1) |
Relevant securities owned |
|
|
|
|
||
|
|
and/or controlled: |
|
|
5,426,879 |
1.00% |
1,607,948 |
0.30% |
|
(2) |
Cash-settled derivatives: |
|
|
|
|
||
|
|
and/or controlled: |
|
|
932,813 |
0.17% |
5,426,840 |
1.00% |
|
(3) |
Stock-settled derivatives (including options) |
|
|
|
|
||
|
|
and agreements to purchase/sell: |
|
|
0 |
0.00% |
0 |
0.00% |
|
|
|
|
|
|
|
|
|
|
|
TOTAL: |
|
|
6,359,692 |
1.17% |
7,034,788 |
1.30% |
|
(b) |
Rights to subscribe for new securities (including directors and other executive |
|
|||||
|
|
options) |
|
|
|
|
|
|
|
Class of relevant security in relation to |
|
|
|
|
|||
|
which subscription right exists |
|
|
|
|
|||
|
Details, including nature of the rights |
|
|
|
|
|||
|
concerned and relevant percentages: |
|
|
|
|
|||
|
3. |
DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER |
||||||
|
(a) |
Purchases and sales |
|
|
|
|
|
|
|
Class of relevant |
Purchase/sale |
Number of |
Price per unit |
||||
|
security |
|
securities |
|
||||
|
1p ordinary |
Purchase |
8,831 |
0.6460 GBP |
||||
|
1p ordinary |
Sale |
3,893 |
0.6460 GBP |
||||
|
1p ordinary |
Sale |
162 |
0.6459 GBP |
||||
|
|
|
|
|
|
|
|
|
|
(b) |
Cash-settled derivative transactions |
|
|||||
|
Class of |
Product |
Nature of dealing |
Number of |
Price per |
|||
|
relevant |
description |
|
reference |
unit |
|||
|
security |
|
|
securities |
|
|||
|
1p ordinary |
SWAP |
Decreasing Short |
162 |
0.6459 GBP |
|||
|
1p ordinary |
SWAP |
Increasing Short |
6,335 |
0.6460 GBP |
|||
|
1p ordinary |
CFD |
Increasing Short |
560 |
0.6460 GBP |
|||
|
|
|
|
|
|
|
|
|
|
(c) |
Stock-settled derivative transactions (including options) |
|
|||||
|
(i) |
Writing, selling, purchasing or varying |
|
|||||
|
Class |
Product |
Writing, |
Number |
Exercise |
Type |
Expiry |
Option |
|
of |
description |
purchasing, |
of |
price |
|
date |
money |
|
relevant |
|
selling, |
securities |
per unit |
|
|
paid/ |
|
security |
|
varying etc |
to which |
|
|
|
received |
|
|
|
|
option |
|
|
|
per unit |
|
|
|
|
relates |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(ii) |
Exercising |
|
|
|
|
|
|
|
Class of relevant |
Product description |
Exercising/ exercised against |
Number of |
Exercise price per |
|||
|
security |
|
|
securities |
unit |
|||
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
(d) |
Other dealings (including subscribing for new securities) |
|
|||||
|
Class of relevant |
Nature of Dealings |
Details |
Price per unit (if |
||||
|
security |
|
|
applicable) |
||||
|
|
|
|
|
||||
|
4. |
OTHER INFORMATION |
||||||
|
(a) |
Indemnity and other dealings arrangements |
|
|||||
|
Details of any indemnity or option arrangement, or any agreement or understanding, |
|
|
|||||
|
formal or informal, relating to relevant securities which may be an inducement to deal |
|
|
|||||
|
or refrain from dealing entered into by the exempt principal trader making the disclosure and any party |
|
||||||
|
to the offer or any person acting in concert with a party to the offer: |
|
|
|
||||
|
NONE |
|||||||
|
(b) |
Agreements, arrangements or understandings relating to options or derivatives |
|
|||||
|
Details of any agreement, arrangement or understanding, formal or informal, between |
|
|
|||||
|
the person making the disclosure and any other person relating to: |
|
|
|||||
|
(i) the voting rights of any relevant securities under any option; or |
|
|
|
||||
|
(ii) the voting rights of future acquisition or disposal of any relevant securities to which |
|
|
|||||
|
any derivative is referenced: |
|
|
|
|
|
|
|
|
NONE |
|||||||
|
(c) |
Attachments |
|
|
|
|
|
|
|
Is a Supplemental Form 8 (Open Positions) attached? |
NO |
||||||
|
Date of disclosure: |
08 May 2025 |
||||||
|
Contact name: |
Large Holdings Regulatory Operations |
||||||
|
Telephone number: |
020 3134 7213 |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|